TCEB1 promotes invasion of prostate cancer cells

International Journal of Cancer

Volumn 124, Issue 1, 2009, Pages 95-102

  Jalava, Sanni E ^a   Porkka, Kati P ^a   Rauhala, Hanna E ^a   Isotalo, Jarkko ^a   Tammela, Teuvo L ^b   Visakorpi, Tapio ^a,b  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Elongin c; Prostatic carcinoma; Rnai

Indexed keywords

INITIATION FACTOR 3; INITIATION FACTOR 3S3; LENTIVIRUS VECTOR; SHORT HAIRPIN RNA; TRANSCRIPTION ELONGATION FACTOR; TRANSCRIPTION ELONGATION FACTOR B POLYPEPTIDE 1; UNCLASSIFIED DRUG; ELONGIN; TRANSCRIPTION FACTOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; GENE; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; KIAA0196 GENE; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; RAD21 GENE; RNA INTERFERENCE; ANIMAL; CELL STRAIN 3T3; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LENTIVIRINAE; MALE; METABOLISM; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LENTIVIRUS; MALE; MICE; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TRANSCRIPTION FACTORS;

EID: 58149393673     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23916     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-8.
3. Ribeiro FR, Jeronimo C, Henrique R, Fonseca D, Oliveira J, Lothe RA, Teixeira MR. 8q Gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects. Clin Cancer Res 2006;12:3961-70.
4. Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-7.
5. van Duin M, van Marion R, Vissers K, Watson JE, van Weerden WM, Schröder FH, Hop WC, van der Kwast TH, Collins C, van Dekken H. High-resolution array comparative genomic hybridization of chromosome arm 8q: evaluation of genetic progression markers for prostate cancer. Genes Chromosomes Cancer 2005;44:438-49.
6. Saramäki OR, Porkka KP, Vessella RL, Visakorpi T. Genetic aberrations in prostate cancer by microarray analysis. Int J Cancer 2006; 119:1322-9.
7. Porkka K, Saramaki O, Tanner M, Visakorpi T. Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. Lab Invest 2002;82:629-37.
8. Porkka KP, Tammela TL, Vessella RL, Visakorpi T. RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes Chromosomes Cancer 2004;39:1-10.
9. Nupponen NN, Porkka K, Kakkola L, Tanner M, Persson K, Borg A, Isola J, Visakorpi T. Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am J Pathol 1999;154:1777-83.
10. Saramäki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L, Visakorpi T. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol 2001;159: 2089-94.
11. Savinainen KJ, Linja MJ, Saramäki OR, Tammela TL, Chang GT, Brinkmann AO, Visakorpi T. Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br J Cancer 2004;90:1041-6.
12. Nasmyth K, Haering CH. The structure and function of SMC and kleisin complexes. Annu Rev Biochem 2005;74:595-648.
13. Pati D, Zhang N, Plon SE. Linking sister chromatid cohesion and apoptosis: role of Rad21. Mol Cell Biol 2002;22:8267-77.
14. Oishi Y, Nagasaki K, Miyata S, Matsuura M, Nishimura S, Akiyama F, Iwai T, Miki Y. Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. J Hum Genet 2007;52:271-9.
15. Atienza JM, Roth RB, Rosette C, Smylie KJ, Kammerer S, Rehbock J, Ekblom J, Denissenko MF. Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. Mol Cancer Ther 2005;4: 361-8.
16. Asano K, Vornlocher HP, Richter-Cook NJ, Merrick WC, Hinnebusch AG, Hershey JW. Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits. Possible roles in RNA binding and macromolecular assembly. J Biol Chem 1997;272:27042-52.
17. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 2003;38:1242-9.
18. Savinainen KJ, Helenius MA, Lehtonen HJ, Visakorpi T. Overexpression of EIF3S3 promotes cancer cell growth. Prostate 2006;66:1144-50.
19. Zhang L, Pan X, Hershey JW. Individual overexpression of five subunits of human translation initiation factor eIF3 promotes malignant transformation of immortal fibroblast cells. J Biol Chem 2007;282: 5790-800.
20. Aso T, Lane WS, Conaway JW, Conaway RC. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995; 269:1439-43.
21. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG Jr. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995;269:1444-6.
22. Kamura T, Sato S, Haque D, Liu L, Kaelin WG Jr, Conaway RC, Conaway JW. The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras. WD-40 repeat, and ankyrin repeat families. Genes Dev 1998;12:3872-81.
23. Rubinson DA, Dillon CP, Kwiatkowski AV, Sievers C, Yang L, Kopinja J, Rooney DL, Zhang M, Ihrig MM, McManus MT, Gertler FB, Scott ML, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003;33:401-6.
24. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics Int 2004;11:36-42.
25. Alexa A, Rahnenfaührer J, Lengauer T. Improved scoring of functional groups from gene expression data by decorrelating GO graph structure. Bioinformatics 2006;22:1600-7.
26. Cockman M, Masson N, Mole D, Jaakkola P, Chang G, Clifford S, Maher E, Pugh C, Ratcliffe P Maxwell P. Hypoxia inducible factor- alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-41.
27. Sufan RI, Jewett MA, Ohh M. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 2004;287:F1-F6.
28. Bullock AN, Debreczeni JE, Edwards AM, Sundström M, Knapp S. Crystal structure of the SOCS2-elongin C-elongin B complex deines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci USA 2006;103:7637-42.
29. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005;115:1503 - 21.
30. Wu I, Moses MA. BNF-1, a novel gene encoding a putative extracellular matrix protein, is overexpressed in tumor tissues. Gene 2003; 311:105-10.
31. Roy R, Wewer UM, Zurakowski D, Pories SE, Moses MA. ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem 2004;279:51323-30.
32. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621-8.
33. Galaup A, Cazes A, Le Jan S, Philippe J, Connault E, Le Coz E, Mekid H, Mir LM, Opolon P, Corvol P, Monnot C, Germain S. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc Natl Acad Sci USA 2006;103:18721-6.
34. Cazes A, Galaup A, Chomel C, Bignon M, Bréchot N, Le Jan S, Weber H, Corvol P, Muller L, Germain S, Monnot C. Extracellular matrix-bound angiopoietin-like 4 inhibits endothelial cell adhesion, migration, and sprouting and alters actin cytoskeleton. Circ Res 2006;99:1207-15.
35. Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, Hsi BL, Byrne JA, et al. Overexpression, amplifcation, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004;64:3814-22.
36. Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res 2007;5:133-44.
37. Knoepfler PS. Myc goes global: new tricks for an old oncogene. Cancer Res 2007;67:5061-3.
38. Tsuchiya N, Kondo Y, Takahashi A, Pawar H, Qian J, Sato K, Lieber MM, Jenkins RB. Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Am J Pathol 2002;160:1799-806.
39. Ribeiro FR, Henrique R, Martins AT, Jerónimo C, Teixeira MR. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol 2007;52:116-25.